Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions

References

• Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. (1999). Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–63.
   PubMed Web of Science ®Google Scholar
• Bachmakov I, Glaeser H, Fromm MF, Konig J. (2008). Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57:1463–69.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32.
   PubMed Web of Science ®Google Scholar
• Campbell SD, de Morais SM, Xu JJ. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179–87.
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51.
   PubMed Web of Science ®Google Scholar
• Chang C, Pang KS, Swaan PW, Ekins S. (2005). Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 314:533–41.
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Leier I, Buchholz U, Keppler D. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–30.
   PubMed Web of Science ®Google Scholar
• Cuiping C, Rouchelle JM, Scott DC, Lin J, Mills JB, Xu JJ, Smolarek TA. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2 and OATP1B1. Drug Metab Dispos 33:537–46.
   Google Scholar
• Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424–33.
   PubMed Web of Science ®Google Scholar
• Elliott JI, Raguz S, Higgins CF. (2004). Multidrug transporter activity in lymphocytes. Br J Pharmacol 143:899–907.
   PubMed Web of Science ®Google Scholar
• Elsby R, Surry DD, Smith VN, Gray AJ. (2008). Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140–64.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Hsiao P, Chung FS, Unadkat JD. (2006). The role of transporters in drug interactions. Eur J Pharm Sci 27:501–17.
   PubMed Web of Science ®Google Scholar
• Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B. (2008). Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57–65.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B. (2007). Organic anion transporting polypeptide (OATP1B1). In:Enna SJ, Bylund DB (Eds) xPharm: The comprehensive pharmacology reference. Elsevier, Online reference. p. 1–3.
   Google Scholar
• Hinton LK, Galetin A, Houston JB. (2008). Multiple inhibition mechanisms and prediction of drug–drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil–drug interactions. Pharm Res 25:1063–74.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–46.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–36.
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–68.
   PubMed Web of Science ®Google Scholar
• Huang SM. (2006). Draft guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. Washington, DC: US Food and Drug Administration (USFDA).
   Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–70.
   PubMed Web of Science ®Google Scholar
• Huang SM, Temple R, Throckmorton DC, Lesko LJ. (2007). Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298–304.
   PubMed Web of Science ®Google Scholar
• Huisman MT, Smit JW, Schinkel AH. (2000). Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:237–42.
   PubMed Web of Science ®Google Scholar
• Kato Y, Suzuki H, Sugiyama Y. (2002). Toxicological implications of hepatobiliary transporters. Toxicology 181–2:287–90.
   Google Scholar
• Koepsell H, Endou H. (2004). The SLC22 drug transporter family. Pflugers Arch 447:666–76.
   PubMed Web of Science ®Google Scholar
• Konig J, Cui Y, Nies AT, Keppler D. (2000). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156–64.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Jung D, Hagenbuch B, Meier PJ. (2002). Organic anion transporting polypeptides, cholestasis, and nuclear receptors. Hepatology 35:732–34.
   Google Scholar
• Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. (2009). Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 296:C570–82.
   PubMed Web of Science ®Google Scholar
• Li L, Lee TK, Meier PJ, Ballatori N. (1998). Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273:16184–91.
   PubMed Web of Science ®Google Scholar
• Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. (2007). Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293:G271–8.
   PubMed Web of Science ®Google Scholar
• Miyagawa M, Maeda K, Aoyama A, Sugiyama Y. (2009). The 8th and 9th transmembrane domains in organic anion transporting polypeptide (OATP) 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17{beta}-D-glucuronide. J Pharmacol Exp Ther 329:551–7.
   PubMed Web of Science ®Google Scholar
• Monks NR, Liu S, Xu Y, Yu H, Bendelow AS, Moscow JA (2007). Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther 6:587–98.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Kusuhara H, Imaoka T, Endou H, Sugiyama Y. (2004). Involvement of rat organic anion transporter 3 in the uptake of an organic herbicide, 2,4-dichlorophenoxyacetate, by the isolated rat choroid plexus. J Pharm Sci 93:2724–32.
   Google Scholar
• Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K. (2001). Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861–67.
   PubMed Web of Science ®Google Scholar
• Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I. (2008). Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet 23:347–355.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47:463–74.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–81.
   PubMed Web of Science ®Google Scholar
• Nießen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S, Kawakami H, Kamiie J, Oswald S, Starke K, Strobel U, Siegmund W, Rosskopf D, Greinacher A, Terasaki T, Kroemer HK. 2009. Human platelets express OATP2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 37:1129–37.
   PubMed Web of Science ®Google Scholar
• Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug–drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14.
   PubMed Web of Science ®Google Scholar
• Sai Y, Tsuji A. (2004). Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today 9:712–20.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. (2002). Transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497–503.
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. (2008). SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359:789–99.
   Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. (2004). Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–36.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425–46.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–16.
   PubMed Web of Science ®Google Scholar
• Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T. (2004). Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–80.
   PubMedGoogle Scholar
• Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. (2001). Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262–69.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. (2005). Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35:737–53.
   PubMed Web of Science ®Google Scholar
• Yengi LG, Leung L, Kao J. (2007). The evolving role of drug metabolism in drug discovery and development. Pharm Res 24:842–58.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–24.
   PubMed Web of Science ®Google Scholar